IlluminaUS4523271090ILMNILMN
Financials
Market Cap
$21.82B5Y beta
1.19EPS (TTM)
-$7.342Free Float
158.46MRevenue (TTM)
$4.50BEBITDA (TTM)
$359.00MFree Cashflow (TTM)
$282.00MPricing
Analyst Ratings
The price target is $155.30 and the stock is covered by 22 analysts.
Buy
8
Hold
11
Sell
3
Information
Illumina, Inc. is a provider of sequencing and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Its Core Illumina segment offers products and services that serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Its GRAIL segment is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis. Its BaseSpace Informatics Suite integrates directly with its sequencing instruments, allowing customers to manage their biological sample and sequencing runs, process and analyze the raw genomic data, and derive results. Its BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that can perform various assays simultaneously.